Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 1Colonic Neoplasms 1

Interventions

Oxaliplatin 14Cetuximab 11Leucovorin 9Fluorouracil 9Magnetic Resonance Spectroscopy 8Nivolumab 7pembrolizumab 6Capecitabine 6encorafenib 5Irinotecan 5Bevacizumab 5dehydroftorafur 4Specimen Handling 4adagrasib 3Immunoglobulin G 3Disulfides 3Biopsy 3selpercatinib 2durvalumab 2cemiplimab 2X-Rays 2Watchful Waiting 2Standard of Care 2Radiotherapy 2Panitumumab 2Observation 2Ipilimumab 2Injections 2Gemcitabine 2Folfox protocol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colonic Neoplasms × epigallocatechin gallate × Clear all
NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡